The outlook for Perrigo Co. PLC's Rx generics business could be on an upswing with the firm forecasting stronger growth in 2018 for the division than for its core businesses, its domestic and international consumer health product units.
The prospects for the Rx business have been questioned for the past year by both analysts and activist investors
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?